D. Boral Capital initiated coverage of CorMedix (CRMD) with a Buy rating and $15 price target CorMedix is at the forefront of infection prevention in dialysis and critical care, with its flagship product, DefenCath, the analyst tells investors in a research note. The firm sees a “compelling value proposition” in mitigating catheter-related bloodstream infections initially in the multi-billion-dollar dialysis market.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD: